Please login to the form below

Not currently logged in
Email:
Password:

MEDI1814

This page shows the latest MEDI1814 news and features for those working in and with pharma, biotech and healthcare.

Biogen rises on more positive data for Alzheimer's candidate

Biogen rises on more positive data for Alzheimer's candidate

compounds. . Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,

Latest news

  • Lilly taps AstraZeneca for another anti-amyloid drug Lilly taps AstraZeneca for another anti-amyloid drug

    Lilly and AZ will collaborate on the development of MEDI1814, an antibody against amyloid-beta 42 (Aβ42), which is currently in phase I trials. ... MEDI1814 dose-dependently reduces levels of the Aβ42 peptide - which is thought to be particularly

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics